Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 8933 results

  1. Artificial Intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: Early Value Assessment

    In development Reference number: GID-HTE10067 Expected publication date:  20 May 2026

    Health technology evaluations
    In development

  2. DCVax-L for treating glioblastoma [ID836]

    In development Reference number: GID-TA10143 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development Reference number: GID-TA11298 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]

    In development Reference number: GID-TA11638 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Awaiting development Reference number: GID-TA11855 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  7. Software for electroencephalogram (EEG) interpretation to support diagnosing epilepsy

    In development Reference number: GID-HTE10086 Expected publication date:  15 September 2026

    Health technology evaluations
    In development

  8. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]

    Awaiting development Reference number: GID-TA11876 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]

    Awaiting development Reference number: GID-TA11659 Expected publication date:  13 May 2027

    Technology appraisal guidance
    Awaiting development

  12. Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]

    In development Reference number: GID-TA11096 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]

    In development Reference number: GID-TA11445 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    Awaiting development Reference number: GID-TA11509 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development